

Freedom of Information Request	FOI 23-523	23 October 2023
--------------------------------	------------	-----------------

Your Request

You requested the following:

- How many patients did you treat with Bypassing agents (BPA)/Hemlibra inhibitor in Q3'23 (July, August, September 2023)?
 - With BPA/Hemlibra Inhibitor?
- Please fill in the BPA/Hemlibra products *utilized* in July, August, and September 2023.

July 1st through September 2023		Q3'23 Volume (IU)/mg		Total Patients	Patients	
					Prophylaxis	On demand
	<i>Example: FEIBA</i>	<i>50,000 IU</i>		<i>1</i>	<i>0</i>	<i>0</i>
Hem A Inhibitor Patients						
Haem A Inhibitor Patients	FEIBA					
	Cevenfacta					
	NovoSeven					
	Hemlibra					
Hem B Inhibitor Patients						
Haem B Inhibitor Patients	FEIBA					
	Cevenfacta					
	NovoSeven					
	Obizur					
AHA Patients						
AHA Patients	FEIBA					
	NovoSeven					
	Obizur					
	Cevenfacta					
	Hemlibra					
Other Use						
FVII deficient	NovoSeven					
Glanzmann's	NovoSeven					
Other	NovoSeven					
Other	Cevenfacta					

- How many minor and major surgeries did your BPA patients have in July, August, and September 2023?

	Inhibitor patients		Glanzmann, FVII deficiency, AHA	
	Minor surgeries	Major surgeries	Minor surgeries	Major surgeries
NovoSeven				
FEIBA				
Obizur				

4. How **many** minor and major surgeries did your BPA/Hemlibra inhibitor patients have in July, August, and September 2023??

	Inhibitor patients		Glanzmann, FVII deficiency, AHA	
	Minor surgeries	Major surgeries	Minor surgeries	Major surgeries
NovoSeven				
FEIBA				
Obizur				

5. How many **breakthrough bleeds** did your Hemlibra Inhibitor patients have, and what brand were they treated with?

	Inhibitor patients	Q3'23 volume (IU/mg)
Hemlibra		
NovoSeven		
FEIBA		

6. Were there any changes in the total number of acute bleeds treated with factor in Q3'23 as compared to Q2'23?

7. Was there any change in the number of elective surgeries **using factor** in Q3'23 as compared to Q2'23?

<i>Number of Surgeries</i>	<i>BPA</i>
Increase / Decrease / Stable compared to Q2'23?	
How many surgeries occurred in Q3'23?	

8. Have any BPA patients switched products between July 1st through September 30th 2023? What were the reasons for the switches?

Indication	Previous Medication	Previous Regimen	Current Medication	Current Regimen	Severity of patient	Reason
<i>Example: Haem B Inh.</i>	<i>1 NovoSeven</i>	<i>On-demand</i>	<i>Cevenfacta</i>	<i>Prophy 1x/week</i>	<i>Severe</i>	<i>Patient requested to try out a new product to improve treatment</i>

9. What is the total number of patients treated with NovoSeven at your center?

Our response

We do not hold the information requested for questions 1 to 9 as we do not stock these products. You may wish to direct your request to [Cardiff and Vale University Health Board](#), which provides care to patients who would require these products.